Deferiprone

證據等級: L5

預測適應症: 9 個

Deferiprone: From Thalassemia Iron Overload to Hepatic Porphyria

One-Sentence Summary

Deferiprone (Ferriprox) is an oral iron chelator with documented FDA and EMA approval for managing iron overload in transfusion-dependent thalassemia major — though it does not appear in the current US regulatory dataset, likely due to a data collection gap. The TxGNN model predicts it may also be effective for Hepatic Porphyria, with 0 clinical trials and 2 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Iron overload in transfusion-dependent thalassemia major (FDA/EMA approved; absent from current dataset — data gap)
Predicted New Indication	Hepatic Porphyria
TxGNN Prediction Score	99.20%
Evidence Level	L4
US Market Status	Not found in dataset (known FDA approval: Ferriprox, 2011 — data gap)
Number of NDAs	0 (data gap)
Recommended Decision	Research Question

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this Evidence Pack (flagged as a high-severity data gap). Based on established pharmacology, deferiprone is a bidentate oral iron chelator that binds ferric iron (Fe³⁺) with high affinity and excretes the resulting complex predominantly via urine. Its unusually small molecular weight allows it to cross cell membranes and mobilize intracellular iron deposits — a property that distinguishes it from other chelators such as deferoxamine and makes it particularly effective at removing cardiac iron in thalassemia patients.

In hepatic porphyria — specifically Porphyria Cutanea Tarda (PCT) and Congenital Erythropoietic Porphyria (CEP) — hepatic iron overload functions as a key pathological trigger. Excess iron catalyzes oxidative reactions that drive the accumulation of uroporphyrin and other phototoxic porphyrin isomers. This iron-porphyrin link is so well established that phlebotomy (iron depletion via bloodletting) is the standard first-line treatment for PCT, directly validating iron removal as a therapeutic strategy. An oral iron chelator such as deferiprone provides a pharmacological route to the same endpoint, and two preclinical studies — detailed below — have already demonstrated this in animal models.

It is critical to note that this mechanistic logic applies only to iron-overload-driven porphyria subtypes (PCT, CEP). For acute hepatic porphyrias such as Acute Intermittent Porphyria (AIP), where the pathology is driven by enzyme dysfunction and ALA/PBG accumulation rather than iron excess, deferiprone would lack direct mechanistic rationale. The TxGNN prediction likely reflects clustering around the shared liver-iron-porphyrin metabolic node in the knowledge graph, making PCT and CEP the clinically meaningful targets for follow-up investigation.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
32678895	2020	Preclinical/Case	Blood	Iron chelation rescued both hemolytic anemia and skin photosensitivity in a mouse model of congenital erythropoietic porphyria (CEP), directly supporting iron removal as a viable therapeutic strategy for porphyrin-accumulation disorders.
17854053	2007	Animal Model	Hepatology	Deferiprone (L1) reduced hepatic uroporphyrin accumulation in Hfe⁻/⁻ mice treated with ALA (a PCT model), performing comparably to iron-deficient diet. Demonstrated that oral iron chelation can substitute for dietary iron restriction in reducing hepatic porphyrin load.

US Market Information

No US FDA authorization records were retrieved for deferiprone in the current dataset.

Data Gap Notice: The repurposing rationale documented in this Evidence Pack explicitly references FDA approval (2011) and EMA approval of Deferiprone (Ferriprox) for transfusion-dependent thalassemia major. The absence of NDA records reflects a data collection failure, not actual non-approval. Verified authorization details should be retrieved directly from FDA Drugs@FDA before clinical development decisions are made.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Research Question

Rationale: Evidence is currently limited to two preclinical and animal model studies (Evidence Level L4) with no registered clinical trials. The mechanistic link between deferiprone’s iron-chelating activity and hepatic porphyria pathology is biologically coherent and supported by animal data, but remains entirely unvalidated in human patients. This warrants a targeted research effort before committing to formal drug development.

To proceed, the following is needed:

Retrieve deferiprone’s full MOA and toxicity profile from DrugBank (DG002 remediation) and FDA package insert for Ferriprox (DG001 remediation — currently blocking S1 safety review)
Narrow the clinical target: distinguish PCT and CEP (mechanistically supported) from AIP and other acute porphyrias (mechanistically unsupported) — the current ICD term “hepatic porphyria” is too broad to guide development
Conduct a broader literature search for PCT + iron chelation ± oral chelator in human cohort or pilot study designs, particularly in patients unable to tolerate phlebotomy
Verify US FDA NDA records for Ferriprox to understand the existing regulatory framework, safety precedents, and labeled contraindications
Identify a natural target population: PCT patients with contraindications to phlebotomy (e.g., severe anemia, poor venous access) could serve as a proof-of-concept cohort with minimal additional safety burden given deferiprone’s established human use in thalassemia
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.